Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Substance Withdrawal Syndrome 1Prostatic Neoplasms 1Melanoma 1Kidney Neoplasms 1Chronic Pain 1Carcinoma, Lobular 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Specimen Handling 3Mastectomy, Segmental 2polyphenon E 1perflutren 1pasireotide 1palbociclib 1fezolinetant 1abemaciclib 1Yoga 1UAB 30 1Tea 1Tamoxifen 1Surgical Procedures, Operative 1Sugars 1Radiotherapy 1Radiation 1Naltrexone 1Mifepristone 1Lapatinib 1Hypericum extract LI 160 1Genotype 1Gefitinib 1Brachytherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Intraductal, Noninfiltrating × Naltrexone × Clear all
NCT02137252 2021-11-16

Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Terminated
3 enrolled 4 charts
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡